NASDAQ: ALECAlector Inc Stock
$2.04-0.11 (-5.12%)
Updated Aug 13, 2026
ALEC Price
$2.04
Fair Value Price
-$0.02
Market Cap
$227.78M
52 Week Low
$1.09
52 Week High
$3.40
P/E
-1.85x
P/B
-22.85x
P/S
16.13x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.86M
Earnings
-$117.85M
Gross Margin
100%
Operating Margin
-847.98%
Profit Margin
-850.1%
Debt to Equity
-21.35
Operating Cash Flow
-$158M
Beta
1.66
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALEC Overview
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALEC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ALEC
Ranked#207 of 464
Ranked#207 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.71 | A | |
| $110.51 | A | |
| $10.90 | A |
Be the first to know about important ALEC news, forecast changes, insider trades & much more!
ALEC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALEC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALEC ($2.04) is overvalued by 12,594.81% relative to our estimate of its Fair Value price of -$0.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALEC ($2.04) is not significantly undervalued (12,594.81%) relative to our estimate of its Fair Value price of -$0.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALEC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALEC due diligence checks available for Premium users.
Valuation
ALEC fair value
Fair Value of ALEC stock based on Discounted Cash Flow (DCF)
Price
$2.04
Fair Value
-$0.02
Undervalued by
12,594.81%
ALEC ($2.04) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALEC ($2.04) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALEC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALEC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.85x
Industry
16.75x
Market
14.17x
ALEC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-22.85x
Industry
5.71x
ALEC's financial health
Profit margin
Revenue
$3.3M
Net Income
-$23.0M
Profit Margin
-692.5%
ALEC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ALEC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$202.9M
Liabilities
$212.8M
Debt to equity
-21.35
ALEC's short-term assets ($180.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALEC's short-term assets ($180.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALEC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALEC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$34.2M
Investing
$17.1M
Financing
$50.0k
ALEC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALEC vs Biotech Stocks
Alector Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.